Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ieso
company
About
Transforming mental healthcare by unlocking the power of clinical data
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $53M
- Industries
- Biotechnology,Health Care,Internet,Psychology,Therapeutics
- Founded date
- Sep 1, 2000
- Number Of Employee
- 101 - 250
- Operating Status
- Active
ieso is a provider of online mental health therapy and develops clinically evidenced assessment and treatment products. ieso's breakthrough discoveries transforms mental healthcare and is revolutionising how the world sees mental health.ieso is building globally scalable digital products and therapeutics for the assessment and treatment of common mood disorders with an additional focus on behaviorally modifiable chronic diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$53M £18M
ieso has raised a total of
$53M £18M
in funding over 2 rounds. Their latest funding was raised on
Nov 23, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 23, 2021 | Series B | $53M | 1 | — | — | Detail |
| Sep 12, 2017 | Series Unknown | £18M | 1 |
Molten Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
ieso is funded by 1 investors.
Molten Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Molten Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
